trial · primary record
OMS906 study drug
C3 Glomerulopathy
| Phase | Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 3 |
| Primary completion | 2026-04-14 |
| Primary endpoint | To assess OMS906 5mg/kg IV administration at 4-week intervals in patients with C3G and ICGN. |
| Registry ID | NCT06209736 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:57.790Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06209736
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.